Following the classification of hepatocellular nodules by the International Working Party in 1995 and further elaboration by the International Consensus Group for Hepatocellular Neoplasia in 2009, entities under the spectrum of hepatocellular nodules have been better characterized. Research work hence has been done to answer questions such as distinguishing high-grade dysplastic nodules from early hepatocellular carcinoma (HCC), delineating the tumor cell origin of HCC, identifying its prognostic markers, and subtyping hepatocellular adenomas. As a result, a copious amount of data at immunohistochemical and molecular levels has emerged. A panel of immunohistochemical markers including glypican-3, heat shock protein 70 and glutamine synthetase has been found to be of use in the diagnosis of small, well differentiated hepatocellular tumors and particularly of HCC. The use of liver fatty acid binding protein (L-FABP), β-catenin, glutamine synthetase, serum amyloid protein and C-reactive protein is found to be helpful in the subtyping of hepatocellular adenomas. The role of tissue biomarkers for prognostication in HCC and the use of biomarkers in subclassifying HCC based on tumor cell origin are also discussed.
Introduction
In 1995, the International Working Party proposed a classification of hepatocellular nodules [1] . Such classification eases communication, as well as facilitates better characterization of each entity under the umbrella of hepatocellular nodular lesions. Under this scheme, hepatocellular nodules were divided into regenerative lesions including focal nodular hyperplasia (FNH), and dysplastic or neoplastic lesions, which comprise hepatocellular adenoma (HCA), dysplastic focus, dysplastic nodule (DN) of low or high grade, and hepatocellular carcinoma (HCC). For lesions showing dysplasia, dysplastic foci by definition measure less than 1 mm; while anything larger than 1 mm belong to DNs [2] . Given this classification, there are major diagnostic issues including differentiating benign nodular lesions (HCA, FNH) from malignant ones; and differentiating DNs, especially high-grade DNs (HGDNs), from early welldifferentiated HCC [3] . iiiiiiiiiiiiii  [4] . Low-grade DNs (LGDNs) are vaguely nodular lesions with peripheral fibrous scar. There is a mild increase in cellularity, yet no cytological atypia, pseudoglands, or thickened trabeculae are observed [4] . HGDNs show architectural and/or cytological atypia featuring increased cell density. Small cell change is the most frequent form of cytological atypia. Nodule-innodule appearance is occasionally seen [4] .
Early HCC, small well-differentiated HCC of vaguely nodular type, shows increased cell density (>2 times than that of surrounding tissue), increased N/C ratio and irregular thin-trabecular pattern. The nodules consist of varying numbers of portal tracts and unpaired arteries. Pseudoglandular pattern and diffuse fatty change are also histological features. One distinguishing feature of HGDN from HCC is the presence of tumor cell invasion into the intratumoral portal tracts in HCC [4] .
Given such detailed histological criteria, distinction of dysplastic from malignant lesions is still sometimes difficult. With the advances in immunohistochemical markers and molecular techniques, this diagnostic problem can be better addressed and attended. Besides, the immunohistochemical and molecular characteristics of hepatocellular nodules have been more explicitly explored. In this review, a brief summary of some recent works of these markers will be illustrated.
HCAs
HCA and FNH are benign hepatic nodules. Diagnosis of these nodules has all along been based on morphological features, which may not always be straightforward. Diagnostic problems include differentiating HCA and FNH (the latter is the most common benign hepatic nodule and carries a lower risk of tumor rupture resulting in hemoperitoneum), as well as differentiating these lesions from HCC.
Besides, various histological features of HCA have aroused researchers' interest to explore further on this benign hepatocellular neoplasm. In recent years, a genotype classification on HCA has been proposed [5] [6] [7] [8] [9] .
According to Bioulac-Sage, et al., such classification of HCA is based on the reasons [8] to: 1) dissect the pathogenesis of HCA, 2) aid diagnosis by radiological means, 3) stratify the risk of progression to HCC, and 4) facilitate genetic screening in familial cases.
The classification of HCA based on genotype consists mainly of three groups: 1) HCA with HNF-1α inactivating gene mutation (H-HCA), 2) HCA with mutation of the -catenin gene (b-HCA), and 3) inflammatory HCA (I-HCA).
Each group of HCA is characterized by the expression of specific genes of interest by quantitative reverse transcription polymerase chain reaction (qRT-PCR) method [9] . FABP1 and UGT2B7, encoding liver fatty acid binding protein (L-FABP) and regulated by HNF-1α, are expressed in normal liver tissues. A low expression of these genes is found in H-HCA cases as compared with other non-mutated subtypes. The expression of the transcripts of GLUL (encoding glutamine synthetase [GS]) and GPR49, two genes regulated by -catenin, correlates with -catenin mutation in the b-HCA subgroup. Up-regulation of SAA2 (encoding serum amyloid A2) and CRP (encoding C-reactive protein) characterizes the I-HCA. Besides, the transcript expression levels by qRT-PCR of the specific genes were found to correlate with the protein expression levels. Immunohistochemical stains thus are useful in classifying HCA based on the immunoprofile [9] . In summary, H-HCA is characterized by a lack of L-FABP staining; b-HCA shows GS (specificity 89%; sensitivity 100%) and -catenin staining (specificity 100%; sensitivity 85%); while I-HCA expresses CRP and SAA (specificity 94%; sensitivity 94%), with or without -catenin [5, 9] . Given the above, 5%10% of HCAs are still unclassifiable [5] .
With reference to the above classification, the clinicopathological features of each group are summarized in Table 1 . H-HCA constitutes about 35%40% of HCA [5] . The mean age of presentation is 39 years and oral contraceptive intake was noted in 92% of cases [7] . It involves bi-allelic inactivating mutations of the HNF-1α gene. Histologically, H-HCA shows marked steatosis, no inflammatory infiltrates and no cytological abnormalities. Immunohistochemically, as mentioned above, there is lack of L-FABP expression among tumor cells in contrast with adjacent liver tissue [5] .
b-HCA constitutes around 10%15% [5] . Oral contraceptive intake is noted in 100% of the cases. Morphologically, occasional cytological abnormalities and rosette formation are observed [7] . Immunohistochemically, aberrant nuclear and cytoplasmic expression is characteristic. Besides, GS, encoded by GLUL, is also expressed in this group of HCA [5] . Recognition of b-HCA is important as it is associated with a higher risk of HCC [10] . I-HCA accounts for more than 50% of HCA [5] . The mean age of presentation is 41 years, and oral contraceptive intake was observed in 90% cases [7] . Clinically, association with high body mass index and alcohol consumption in patients is observed. Signs of inflammatory syndromes, e.g. raised CRP levels, are noted. Histologically, features of I-HCA include inflammatory infiltrates, sinusoidal dilatation or congestion, presence of thick-wall arteries (some being dystrophic), and ductular reaction. Steatosis may be present but not as extensive [5, 7] . In addition, there is increased expression of SAA and CRP at mRNA and protein levels, and can be detected by immunohistochemical methods [5] .
FNH
FNH is not subjected to classification at this stage.
